Dabigatran performs well in study

01/3/2013 | Healio

The anticoagulant dabigatran performed safely and effectively in a group of 938 unselected patients with atrial fibrillation, according to a German study presented at a meeting. Less than 2% of the patients experienced major cardiovascular events, and 1% experienced minor cardiovascular events. Bleeding complications were experienced by 14.9% of patients, but only 1.5% faced major bleeding, the study found.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA